Saturday 17 October 2026
Export CTMX’s income statement to Excel — free account
CytomX Therapeutics, Inc.
CTMX Healthcare Biotechnology
CytomX Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $76.2 million, down 44.8% from fiscal 2024. In the quarter to June 2026, revenue fell 92.4%, EPS fell 7,400.0% and free cash flow fell 14.5%, each against the same quarter a year earlier.
2.27
0.14
−5.81%
Follow CTMX
CytomX Therapeutics, Inc. (CTMX) P/E ratio
CytomX Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 25.7× (May 2024) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 2.7× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 8.0× | 96.91% |
| 42 more quarters | Free account |
Against its own ten years
Low 0.0×
High 25.7×
Ten-year median
0.0×
Current reading's percentile
84
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| CTMX CytomX Therapeutics, Inc. | n/m |
| STTK Shattuck Labs, Inc. compare | n/m |
| FTH Faeth Therapeutics, Inc. compare | n/m |
| VECT VectivBio Holding AG compare | n/m |
| CYVNY Ceryvyn Therapeutics Ltd. - Unsponsored ADR compare | n/m |
| ACRS Aclaris Therapeutics, Inc. compare | n/m |
| DRUG Bright Minds Biosciences Inc. compare | n/m |
| PBYI Puma Biotechnology, Inc. compare | 18.2× |
| VALN Valneva SE Sponsored ADR compare | 59.7× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)